176 related articles for article (PubMed ID: 17080443)
1. Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations.
Schüpbach M; Lohmann E; Anheim M; Lesage S; Czernecki V; Yaici S; Worbe Y; Charles P; Welter ML; Pollak P; Dürr A; Agid Y; Brice A
Mov Disord; 2007 Jan; 22(1):119-22. PubMed ID: 17080443
[TBL] [Abstract][Full Text] [Related]
2. The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.
Greenbaum L; Israeli-Korn SD; Cohen OS; Elincx-Benizri S; Yahalom G; Kozlova E; Strauss H; Molshatzki N; Inzelberg R; Spiegelmann R; Israel Z; Hassin-Baer S
Parkinsonism Relat Disord; 2013 Nov; 19(11):1053-6. PubMed ID: 23932063
[TBL] [Abstract][Full Text] [Related]
3. Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers.
Sayad M; Zouambia M; Chaouch M; Ferrat F; Nebbal M; Bendini M; Lesage S; Brice A; Brahim Errahmani M; Asselah B
BMC Neurosci; 2016 Feb; 17():6. PubMed ID: 26831335
[TBL] [Abstract][Full Text] [Related]
4. Sustained response to deep brain stimulation in LRRK2 parkinsonism with the Y1699C mutation.
Perju-Dumbrava LD; McDonald M; Kneebone AC; Long R; Thyagarajan D
J Parkinsons Dis; 2012; 2(4):269-71. PubMed ID: 23938256
[TBL] [Abstract][Full Text] [Related]
5. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
[TBL] [Abstract][Full Text] [Related]
6. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.
Lesage S; Janin S; Lohmann E; Leutenegger AL; Leclere L; Viallet F; Pollak P; Durif F; Thobois S; Layet V; Vidailhet M; Agid Y; Dürr A; Brice A; ; Bonnet AM; Borg M; Broussolle E; Damier P; Destée A; Martinez M; Penet C; Rasco O; Tison F; Tranchan C; Vérin M
Arch Neurol; 2007 Mar; 64(3):425-30. PubMed ID: 17353388
[TBL] [Abstract][Full Text] [Related]
7. Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain.
González-Fernández MC; Lezcano E; Ross OA; Gómez-Esteban JC; Gómez-Busto F; Velasco F; Alvarez-Alvarez M; Rodríguez-Martínez MB; Ciordia R; Zarranz JJ; Farrer MJ; Mata IF; de Pancorbo MM
Parkinsonism Relat Disord; 2007 Dec; 13(8):509-15. PubMed ID: 17540608
[TBL] [Abstract][Full Text] [Related]
8. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
[TBL] [Abstract][Full Text] [Related]
9. Unilateral pallidotomy in a patient with parkinsonism and G2019S LRRK2 mutation.
Munhoz RP; Teive HA; Francisco AN; Raskin S; Rogaeva E
Mov Disord; 2009 Apr; 24(5):791-2; author reply 792. PubMed ID: 19012346
[No Abstract] [Full Text] [Related]
10. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
Huang Y; Halliday GM; Vandebona H; Mellick GD; Mastaglia F; Stevens J; Kwok J; Garlepp M; Silburn PA; Horne MK; Kotschet K; Venn A; Rowe DB; Rubio JP; Sue CM
Mov Disord; 2007 May; 22(7):982-9. PubMed ID: 17427941
[TBL] [Abstract][Full Text] [Related]
11. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism.
van Nuenen BF; Helmich RC; Ferraye M; Thaler A; Hendler T; Orr-Urtreger A; Mirelman A; Bressman S; Marder KS; Giladi N; van de Warrenburg BP; Bloem BR; Toni I;
Brain; 2012 Dec; 135(Pt 12):3687-98. PubMed ID: 23250886
[TBL] [Abstract][Full Text] [Related]
12. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
[TBL] [Abstract][Full Text] [Related]
13. Analysis of deep brain stimulation of the subthalamic nucleus (STN-DBS) in patients with monogenic PRKN and LRRK2 forms of Parkinson's disease.
Prendes Fernández P; Blázquez Estrada M; Sol Álvarez J; Álvarez Martínez V; Suárez San Martín E; García Fernández C; Álvarez Carriles JC; Lozano Aragoneses B; Saiz Ayala A; Santamarta Liébana E; González Álvarez L
Parkinsonism Relat Disord; 2023 Feb; 107():105282. PubMed ID: 36657280
[TBL] [Abstract][Full Text] [Related]
14. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
[TBL] [Abstract][Full Text] [Related]
15. G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia.
Pchelina SN; Yakimovskii AF; Ivanova ON; Emelianov AK; Zakharchuk AH; Schwarzman AL
Mov Disord; 2006 Dec; 21(12):2234-6. PubMed ID: 17044089
[TBL] [Abstract][Full Text] [Related]
16. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.
Tan EK; Skipper L; Chua E; Wong MC; Pavanni R; Bonnard C; Kolatkar P; Liu JJ
Mov Disord; 2006 Jul; 21(7):997-1001. PubMed ID: 16602113
[TBL] [Abstract][Full Text] [Related]
17. Parkinsonism, Lrrk2 G2019S, and tau neuropathology.
Rajput A; Dickson DW; Robinson CA; Ross OA; Dächsel JC; Lincoln SJ; Cobb SA; Rajput ML; Farrer MJ
Neurology; 2006 Oct; 67(8):1506-8. PubMed ID: 17060589
[TBL] [Abstract][Full Text] [Related]
18. Olfactory heterogeneity in LRRK2 related Parkinsonism.
Silveira-Moriyama L; Munhoz RP; de J Carvalho M; Raskin S; Rogaeva E; de C Aguiar P; Bressan RA; Felicio AC; Barsottini OG; Andrade LA; Chien HF; Bonifati V; Barbosa ER; Teive HA; Lees AJ
Mov Disord; 2010 Dec; 25(16):2879-83. PubMed ID: 20818658
[TBL] [Abstract][Full Text] [Related]
19. Co-occurrence of sporadic parkinsonism and late-onset Alzheimer's disease in a Brazilian male with the LRRK2 p.G2019S mutation.
Santos-Rebouças CB; Abdalla CB; Baldi FJ; Martins PA; Corrêa JC; Gonçalves AP; Cunha MS; Borges MB; Pereira JS; Laks J; Pimentel MM
Genet Test; 2008 Dec; 12(4):471-3. PubMed ID: 19072560
[TBL] [Abstract][Full Text] [Related]
20. Juvenile-onset parkinsonism with digenic parkin and PINK1 mutations treated with subthalamic nucleus stimulation at 45 years after disease onset.
Nakahara K; Ueda M; Yamada K; Koide T; Yoshimochi G; Funayama M; Kim JH; Yamakawa S; Mori A; Misumi Y; Uyama E; Hattori N; Ando Y
J Neurol Sci; 2014 Oct; 345(1-2):276-7. PubMed ID: 25106695
[No Abstract] [Full Text] [Related]
[Next] [New Search]
